Privacy Consent on FHIR (PCF)
1.1.1-current - ci-build

Privacy Consent on FHIR (PCF), published by IHE IT Infrastructure Technical Committee. This guide is not an authorized publication; it is the continuous build for version 1.1.1-current built by the FHIR (HL7® FHIR® Standard) CI Build. This version is based on the current content of https://github.com/IHE/ITI.PCF/ and changes regularly. See the Directory of published versions

## ValueSet: clinical codes that indicate HIV (Experimental)

Official URL: https://profiles.ihe.net/ITI/PCF/ValueSet/SlsSensitiveHIV | Version: 1.1.1-current
Draft as of 2025-10-07 | Computable Name: SlsSensitiveHIV

HIV/AIDS information

- SAMSHA C2S HIV/AIDS Information
  - ValueSet 2.16.840.1.113762.1.4.1142.23 // HCPCS
  - ValueSet 2.16.840.1.113762.1.4.1142.24 // ICD9CM
  - ValueSet 2.16.840.1.113762.1.4.1142.25 // LOINC
  - ValueSet 2.16.840.1.113762.1.4.1142.26 // RXNORM
  - ValueSet 2.16.840.1.113762.1.4.1142.27 // SNOMED-CT
  - ValueSet 2.16.840.1.113762.1.4.1142.60 // CPT
- SAMSHA Test C2S HIV/AIDS Information Sensitivity
  - ValueSet 2.16.840.1.113762.1.4.1142.67 // SNOMEDCD

References

This value set is not used here; it may be used elsewhere (e.g. specifications and/or implementations that use this content)

### Logical Definition (CLD)

This value set includes codes based on the following rules:

- Import all the codes that are contained in C2S HIV/AIDS Information Sensitivity
- Import all the codes that are contained in C2S HIV/AIDS Information Sensitivity
- Import all the codes that are contained in C2S HIV/AIDS Information Sensitivity
- Import all the codes that are contained in C2S HIV/AIDS Information Sensitivity
- Import all the codes that are contained in C2S HIV/AIDS Information Sensitivity
- Import all the codes that are contained in C2S HIV/AIDS information Sensitivity
- Import all the codes that are contained in Test C2S HIV/AIDS Information Sensitivity

### Expansion

Expansion from tx.fhir.org based on:

- valueset C2S HIV/AIDS Information Sensitivity v20160909 (ValueSet)
- valueset C2S HIV/AIDS Information Sensitivity v20160909 (ValueSet)
- valueset C2S HIV/AIDS Information Sensitivity v20160909 (ValueSet)
- valueset C2S HIV/AIDS Information Sensitivity v20160909 (ValueSet)
- valueset C2S HIV/AIDS Information Sensitivity v20160909 (ValueSet)
- valueset C2S HIV/AIDS information Sensitivity v20160909 (ValueSet)
- valueset Test C2S HIV/AIDS Information Sensitivity v20190216 (ValueSet)

This value set contains 162 concepts

Code | System | Display
0575F | http://www.nlm.nih.gov/research/umls/hcpcs | Hiv rna control plan of care, documented (hiv)
3292F | http://www.nlm.nih.gov/research/umls/hcpcs | Hiv testing ordered or documented and reviewed during the first or second prenatal visit (pre-cr)
3490F | http://www.nlm.nih.gov/research/umls/hcpcs | History of aids-defining condition (hiv)
3491F | http://www.nlm.nih.gov/research/umls/hcpcs | Hiv indeterminate (infants of undetermined hiv status born of hiv-infected mothers) (hiv)
3492F | http://www.nlm.nih.gov/research/umls/hcpcs | History of nadir cd4+ cell count <350 cells/mm (hiv)
3493F | http://www.nlm.nih.gov/research/umls/hcpcs | No history of nadir cd4+ cell count <350 cells/mmand no history of aids-defining condition (hiv)
3494F | http://www.nlm.nih.gov/research/umls/hcpcs | Cd4+ cell count <200 cells/mm3 (hiv)
3495F | http://www.nlm.nih.gov/research/umls/hcpcs | Cd4+ cell count 200 - 499 cells/mm3 (hiv)
3496F | http://www.nlm.nih.gov/research/umls/hcpcs | Cd4+ cell count >=500 cells/mm3 (hiv)
3497F | http://www.nlm.nih.gov/research/umls/hcpcs | Cd4+ cell percentage <15% (hiv)
3498F | http://www.nlm.nih.gov/research/umls/hcpcs | Cd4+ cell percentage >/=15% (hiv)
3500F | http://www.nlm.nih.gov/research/umls/hcpcs | Cd4+ cell count or cd4+ cell percentage documented as performed (hiv)
3502F | http://www.nlm.nih.gov/research/umls/hcpcs | Hiv rna viral load below limits of quantification (hiv)
3503F | http://www.nlm.nih.gov/research/umls/hcpcs | Hiv rna viral load not below limits of quantification (hiv)
3510F | http://www.nlm.nih.gov/research/umls/hcpcs | Documentation that tuberculosis (tb) screening test performed and results interpreted (hiv) (ibd)
3511F | http://www.nlm.nih.gov/research/umls/hcpcs | Chlamydia and gonorrhea screenings documented as performed (hiv)
3512F | http://www.nlm.nih.gov/research/umls/hcpcs | Syphilis screening documented as performed (hiv)
3513F | http://www.nlm.nih.gov/research/umls/hcpcs | Hepatitis b screening documented as performed (hiv)
3514F | http://www.nlm.nih.gov/research/umls/hcpcs | Hepatitis c screening documented as performed (hiv)
3515F | http://www.nlm.nih.gov/research/umls/hcpcs | Patient has documented immunity to hepatitis c (hiv)
4149F | http://www.nlm.nih.gov/research/umls/hcpcs | Hepatitis b vaccine injection administered or previously received (hep-c, hiv) (ibd)
4270F | http://www.nlm.nih.gov/research/umls/hcpcs | Patient receiving potent antiretroviral therapy for 6 months or longer (hiv)
4271F | http://www.nlm.nih.gov/research/umls/hcpcs | Patient receiving potent antiretroviral therapy for less than 6 months or not receiving potent antiretroviral therapy (hiv)
4274F | http://www.nlm.nih.gov/research/umls/hcpcs | Influenza immunization administered or previously received (hiv) (p-esrd)
4276F | http://www.nlm.nih.gov/research/umls/hcpcs | Potent antiretroviral therapy prescribed (hiv)
4279F | http://www.nlm.nih.gov/research/umls/hcpcs | Pneumocystis jiroveci pneumonia prophylaxis prescribed (hiv)
4280F | http://www.nlm.nih.gov/research/umls/hcpcs | Pneumocystis jiroveci pneumonia prophylaxis prescribed within 3 months of low cd4+ cell count or percentage (hiv)
4290F | http://www.nlm.nih.gov/research/umls/hcpcs | Patient screened for injection drug use (hiv)
4293F | http://www.nlm.nih.gov/research/umls/hcpcs | Patient screened for high-risk sexual behavior (hiv)
86689 | http://www.nlm.nih.gov/research/umls/hcpcs | Confirmation test for antibody to Human T-cell lymphotropic virus (HTLV) or HIV
86701 | http://www.nlm.nih.gov/research/umls/hcpcs | Analysis for antibody to HIV -1 virus
86702 | http://www.nlm.nih.gov/research/umls/hcpcs | Analysis for antibody to HIV-2 virus
86703 | http://www.nlm.nih.gov/research/umls/hcpcs | Analysis for antibody to HIV-1 and HIV-2 virus
87389 | http://www.nlm.nih.gov/research/umls/hcpcs | Detection test by immunoassay technique for HIV-1 antigen and HIV-1 and HIV-2 antibodies
87390 | http://www.nlm.nih.gov/research/umls/hcpcs | Detection test by immunoassay technique for HIV-1 antigen
87391 | http://www.nlm.nih.gov/research/umls/hcpcs | Detection test by immunoassay technique for HIV-2 antigen
87534 | http://www.nlm.nih.gov/research/umls/hcpcs | Detection test by nucleic acid for HIV-1 virus, direct probe technique
87535 | http://www.nlm.nih.gov/research/umls/hcpcs | Detection test by nucleic acid for HIV-1 virus, amplified probe technique
87536 | http://www.nlm.nih.gov/research/umls/hcpcs | Detection test by nucleic acid for HIV-1 virus, quantification
87537 | http://www.nlm.nih.gov/research/umls/hcpcs | Detection test by nucleic acid for HIV-2 virus, direct probe technique
87538 | http://www.nlm.nih.gov/research/umls/hcpcs | Detection test by nucleic acid for HIV-2 virus, amplified probe technique
87539 | http://www.nlm.nih.gov/research/umls/hcpcs | Detection test by nucleic acid for HIV-2 virus, quantification
87900 | http://www.nlm.nih.gov/research/umls/hcpcs | Infectious agent drug susceptibility analysis
87901 | http://www.nlm.nih.gov/research/umls/hcpcs | Analysis test by nucleic acid for HIV-1 virus
87903 | http://www.nlm.nih.gov/research/umls/hcpcs | Analysis test by nucleic acid for HIV-1 virus, first through 10 drugs tested
87904 | http://www.nlm.nih.gov/research/umls/hcpcs | Analysis test by nucleic acid for HIV-1 virus, each additional drug tested
87906 | http://www.nlm.nih.gov/research/umls/hcpcs | Analysis test by nucleic acid for HIV-1 virus, other region
G0432 | http://www.nlm.nih.gov/research/umls/hcpcs | Infectious agent antibody detection by enzyme immunoassay (eia) technique, hiv-1 and/or hiv-2, screening
G0433 | http://www.nlm.nih.gov/research/umls/hcpcs | Infectious agent antibody detection by enzyme-linked immunosorbent assay (elisa) technique, hiv-1 and/or hiv-2, screening
G0435 | http://www.nlm.nih.gov/research/umls/hcpcs | Infectious agent antibody detection by rapid antibody test, hiv-1 and/or hiv-2, screening
S3645 | http://www.nlm.nih.gov/research/umls/hcpcs | Hiv-1 antibody testing of oral mucosal transudate
136.3 | http://hl7.org/fhir/sid/icd-9-cm | Pneumocystosis
176.9 | http://hl7.org/fhir/sid/icd-9-cm | Kaposi's sarcoma, unspecified site
42 | http://hl7.org/fhir/sid/icd-9-cm | Operations on esophagus
10901-7 | http://loinc.org | HIV 2 gp125 Ab [Presence] in Serum by Immunoblot
10902-5 | http://loinc.org | HIV 2 gp36 Ab [Presence] in Serum by Immunoblot
11078-3 | http://loinc.org | HIV 2 gp80 Ab [Presence] in Serum by Immunoblot
11079-1 | http://loinc.org | HIV 2 p26 Ab [Presence] in Serum by Immunoblot
11080-9 | http://loinc.org | HIV 2 p53 Ab [Presence] in Serum by Immunoblot
11081-7 | http://loinc.org | HIV 2 p56 Ab [Presence] in Serum by Immunoblot
11082-5 | http://loinc.org | HIV 2 p68 Ab [Presence] in Serum by Immunoblot
13920-4 | http://loinc.org | HIV 2 p41 Ab [Presence] in Serum by Immunoblot
21334-8 | http://loinc.org | HIV 2 gp105 Ab [Presence] in Serum by Immunoblot
21335-5 | http://loinc.org | HIV 2 gp120 Ab [Presence] in Serum by Immunoblot
21336-3 | http://loinc.org | HIV 2 gp15 Ab [Presence] in Serum by Immunoblot
21337-1 | http://loinc.org | HIV 2 gp34 Ab [Presence] in Serum by Immunoblot
21338-9 | http://loinc.org | HIV 2 p31 Ab [Presence] in Serum by Immunoblot
21339-7 | http://loinc.org | HIV 2 p55 Ab [Presence] in Serum by Immunoblot
21340-5 | http://loinc.org | HIV 2 p58 Ab [Presence] in Serum by Immunoblot
22358-6 | http://loinc.org | HIV 2 Ab [Units/volume] in Serum
25841-8 | http://loinc.org | HIV 2 proviral DNA [Presence] in Blood by NAA with probe detection
25842-6 | http://loinc.org | HIV 2 proviral DNA [Presence] in Specimen by NAA with probe detection
30361-0 | http://loinc.org | HIV 2 Ab [Presence] in Serum or Plasma by Immunoassay
31073-0 | http://loinc.org | HIV 2 Ab band pattern [Interpretation] in Serum by Immunoblot
33806-1 | http://loinc.org | HIV 2 IgG Ab [Presence] in Serum by Immunoblot
33807-9 | http://loinc.org | HIV 2 IgG Ab [Presence] in Serum
34699-9 | http://loinc.org | HIV 2 proviral DNA [Presence] in Serum or Plasma by NAA with probe detection
42768-2 | http://loinc.org | HIV 1 and 2 Ab [Interpretation] in Serum Narrative
43185-8 | http://loinc.org | HIV 1 and 2 Ab band pattern [Interpretation] in Serum by Immunoblot
45212-8 | http://loinc.org | HIV 2 p31+p34 Ab [Presence] in Serum by Immunoblot
47029-4 | http://loinc.org | HIV 2 Ab [Presence] in Cerebral spinal fluid by Immunoblot
51786-2 | http://loinc.org | HIV 2 Ab Signal/Cutoff in Serum or Plasma by Immunoassay
5224-1 | http://loinc.org | HIV 2 Ab [Units/volume] in Serum or Plasma by Immunoassay
5225-8 | http://loinc.org | HIV 2 Ab [Presence] in Serum by Immunoblot
56888-1 | http://loinc.org | HIV 1+2 Ab+HIV1 p24 Ag [Presence] in Serum or Plasma by Immunoassay
57976-3 | http://loinc.org | HIV 2 gp140 Ab [Presence] in Serum by Immunoblot
57977-1 | http://loinc.org | HIV 2 p16 Ab [Presence] in Serum by Immunoblot
57978-9 | http://loinc.org | HIV 2 p34 Ab [Presence] in Serum by Immunoblot
58900-2 | http://loinc.org | HIV 1+2 Ab+HIV1 p24 Ag [Units/volume] in Serum or Plasma by Immunoassay
62456-9 | http://loinc.org | HIV 2 p15 Ab [Presence] in Serum by Immunoblot
6429-5 | http://loinc.org | HIV identified in Blood by Organism specific culture
6430-3 | http://loinc.org | HIV identified in Semen by Organism specific culture
6431-1 | http://loinc.org | HIV identified in Specimen by Organism specific culture
69353-1 | http://loinc.org | HIV 2 RNA [Presence] in Serum or Plasma by NAA with probe detection
69354-9 | http://loinc.org | HIV 2 RNA [Units/volume] (viral load) in Serum or Plasma by NAA with probe detection
69668-2 | http://loinc.org | HIV 1 and 2 Ab [Identifier] in Serum or Plasma by Rapid immunoassay
7919-4 | http://loinc.org | HIV 2 Ab [Presence] in Serum
9836-8 | http://loinc.org | HIV proviral DNA [Presence] in Blood by Probe with amplification
LP14307-0 | http://loinc.org | HIV 1
LP16715-2 | http://loinc.org | HIV 1+2
LP16716-0 | http://loinc.org | HIV 2
LP29063-2 | http://loinc.org | HIV reverse transcriptase gene
LP30901-0 | http://loinc.org | HIV protease gene
LP32723-6 | http://loinc.org | HIV reverse transcriptase+protease gene
LP36650-7 | http://loinc.org | HIV 1 & 2
LP36876-8 | http://loinc.org | HIV nucleoside reverse transcriptase gene
LP36877-6 | http://loinc.org | HIV nonnucleoside reverse transcriptase gene
LP38420-3 | http://loinc.org | HIV identified
LP38459-1 | http://loinc.org | HIV 1+2 Ab
LP38463-3 | http://loinc.org | HIV 2 Ab
LP62411-1 | http://loinc.org | HIV 1+O+2 Ab
152535 | http://www.nlm.nih.gov/research/umls/rxnorm | Zovirax
281 | http://www.nlm.nih.gov/research/umls/rxnorm | acyclovir
111880001 | http://snomed.info/sct | Acute human immunodeficiency virus infection (disorder)
420721002 | http://snomed.info/sct | Acquired immunodeficiency syndrome-associated disorder (disorder)
0575F | http://www.ama-assn.org/go/cpt | HIV RNA control plan of care, documented (HIV)
3292F | http://www.ama-assn.org/go/cpt | HIV testing ordered or documented and reviewed during the first or second prenatal visit (Pre-Cr)
3490F | http://www.ama-assn.org/go/cpt | History of AIDS-defining condition (HIV)
3491F | http://www.ama-assn.org/go/cpt | HIV indeterminate (infants of undetermined HIV status born of HIV-infected mothers) (HIV)
3492F | http://www.ama-assn.org/go/cpt | History of nadir CD4+ cell count <350 cells/mm3 (HIV)
3493F | http://www.ama-assn.org/go/cpt | No history of nadir CD4+ cell count <350 cells/mm3 and no history of AIDS-defining condition (HIV)
3494F | http://www.ama-assn.org/go/cpt | CD4+ cell count <200 cells/mm3 (HIV)
3495F | http://www.ama-assn.org/go/cpt | CD4+ cell count 200 - 499 cells/mm3 (HIV)
3496F | http://www.ama-assn.org/go/cpt | CD4+ cell count >/=500 cells/mm3 (HIV)
3497F | http://www.ama-assn.org/go/cpt | CD4+ cell percentage <15% (HIV)
3498F | http://www.ama-assn.org/go/cpt | CD4+ cell percentage >/=15% (HIV)
3500F | http://www.ama-assn.org/go/cpt | CD4+ cell count or CD4+ cell percentage documented as performed (HIV)
3502F | http://www.ama-assn.org/go/cpt | HIV RNA viral load below limits of quantification (HIV)
3503F | http://www.ama-assn.org/go/cpt | HIV RNA viral load not below limits of quantification (HIV)
3510F | http://www.ama-assn.org/go/cpt | Documentation that tuberculosis (TB) screening test performed and results interpreted (HIV) (IBD)
3511F | http://www.ama-assn.org/go/cpt | Chlamydia and gonorrhea screenings documented as performed (HIV)
3512F | http://www.ama-assn.org/go/cpt | Syphilis screening documented as performed (HIV)
3513F | http://www.ama-assn.org/go/cpt | Hepatitis B screening documented as performed (HIV)
3514F | http://www.ama-assn.org/go/cpt | Hepatitis C screening documented as performed (HIV)
3515F | http://www.ama-assn.org/go/cpt | Patient has documented immunity to Hepatitis C (HIV)
4149F | http://www.ama-assn.org/go/cpt | Hepatitis B vaccine injection administered or previously received (HEP-C, HIV) (IBD)
4270F | http://www.ama-assn.org/go/cpt | Patient receiving potent antiretroviral therapy for 6 months or longer (HIV)
4271F | http://www.ama-assn.org/go/cpt | Patient receiving potent antiretroviral therapy for less than 6 months or not receiving potent antiretroviral therapy (HIV)
4274F | http://www.ama-assn.org/go/cpt | Influenza immunization administered or previously received (HIV) (P-ESRD)
4276F | http://www.ama-assn.org/go/cpt | Potent antiretroviral therapy prescribed (HIV)
4279F | http://www.ama-assn.org/go/cpt | Pneumocystis jiroveci pneumonia prophylaxis prescribed (HIV)
4280F | http://www.ama-assn.org/go/cpt | Pneumocystis jiroveci pneumonia prophylaxis prescribed within 3 months of low CD4+ cell count or percentage (HIV)
4290F | http://www.ama-assn.org/go/cpt | Patient screened for injection drug use (HIV)
4293F | http://www.ama-assn.org/go/cpt | Patient screened for high-risk sexual behavior (HIV)
86689 | http://www.ama-assn.org/go/cpt | Antibody; HTLV or HIV antibody, confirmatory test (eg, Western Blot)
86701 | http://www.ama-assn.org/go/cpt | Antibody; HIV-1
86702 | http://www.ama-assn.org/go/cpt | Antibody; HIV-2
86703 | http://www.ama-assn.org/go/cpt | Antibody; HIV-1 and HIV-2, single result
87389 | http://www.ama-assn.org/go/cpt | Infectious agent antigen detection by immunoassay technique (eg, enzyme immunoassay [EIA], enzyme-linked immunosorbent assay [ELISA], fluorescence immunoassay [FIA], immunochemiluminometric assay [IMCA]), qualitative or semiquantitative; HIV-1 antigen(s), with HIV-1 and HIV-2 antibodies, single result
87390 | http://www.ama-assn.org/go/cpt | Infectious agent antigen detection by immunoassay technique (eg, enzyme immunoassay [EIA], enzyme-linked immunosorbent assay [ELISA], fluorescence immunoassay [FIA], immunochemiluminometric assay [IMCA]), qualitative or semiquantitative; HIV-1
87391 | http://www.ama-assn.org/go/cpt | Infectious agent antigen detection by immunoassay technique (eg, enzyme immunoassay [EIA], enzyme-linked immunosorbent assay [ELISA], fluorescence immunoassay [FIA], immunochemiluminometric assay [IMCA]), qualitative or semiquantitative; HIV-2
87534 | http://www.ama-assn.org/go/cpt | Infectious agent detection by nucleic acid (DNA or RNA); HIV-1, direct probe technique
87535 | http://www.ama-assn.org/go/cpt | Infectious agent detection by nucleic acid (DNA or RNA); HIV-1, amplified probe technique, includes reverse transcription when performed
87536 | http://www.ama-assn.org/go/cpt | Infectious agent detection by nucleic acid (DNA or RNA); HIV-1, quantification, includes reverse transcription when performed
87537 | http://www.ama-assn.org/go/cpt | Infectious agent detection by nucleic acid (DNA or RNA); HIV-2, direct probe technique
87538 | http://www.ama-assn.org/go/cpt | Infectious agent detection by nucleic acid (DNA or RNA); HIV-2, amplified probe technique, includes reverse transcription when performed
87539 | http://www.ama-assn.org/go/cpt | Infectious agent detection by nucleic acid (DNA or RNA); HIV-2, quantification, includes reverse transcription when performed
87900 | http://www.ama-assn.org/go/cpt | Infectious agent drug susceptibility phenotype prediction using regularly updated genotypic bioinformatics
87901 | http://www.ama-assn.org/go/cpt | Infectious agent genotype analysis by nucleic acid (DNA or RNA); HIV-1, reverse transcriptase and protease regions
87903 | http://www.ama-assn.org/go/cpt | Infectious agent phenotype analysis by nucleic acid (DNA or RNA) with drug resistance tissue culture analysis, HIV 1; first through 10 drugs tested
87904 | http://www.ama-assn.org/go/cpt | Infectious agent phenotype analysis by nucleic acid (DNA or RNA) with drug resistance tissue culture analysis, HIV 1; each additional drug tested (List separately in addition to code for primary procedure)
87906 | http://www.ama-assn.org/go/cpt | Infectious agent genotype analysis by nucleic acid (DNA or RNA); HIV-1, other region (eg, integrase, fusion)

Explanation of the columns that may appear on this page:

Level | A few code lists that FHIR defines are hierarchical - each code is assigned a level. In this scheme, some codes are under other codes, and imply that the code they are under also applies
System | The source of the definition of the code (when the value set draws in codes defined elsewhere)
Code | The code (used as the code in the resource instance)
Display | The display (used in the display element of a Coding). If there is no display, implementers should not simply display the code, but map the concept into their application
Definition | An explanation of the meaning of the concept
Comments | Additional notes about how to use the code

History

Date | Action | Author | Verifier | Comment
2023-01-31 | revise | John Moehrke |  | Administrative touchup to add history
2022-07-27 | create | John Moehrke | John F. Moehrke | Initial ValueSet as per the C2S layout